Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health - 2When fake data is a good thing – how synthetic data trains AI to solve real problems
- 3Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- 4Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage
- 5Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- Pick the Ideal Family Feline Variety for Your Home
- The Best Cell phone Brands for Tech Lovers
- Report in relation to renaming Herzog Park set to be withdrawn
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Happy with Running Shoes for 2024
- Indonesian Mega-Farm Drives Surge in Deforestation
- All that You Really want to Be aware of Dental Inserts Facilities
- Investigating Inside Plan and Home Style: Change Your Residing Space
- The Fragrant Small Tree Birds & Pollinators Love With Stunning Flowers In Summer
